This round of financing will be used for the research and development iteration of the company's vascular interventional surgery robot, the expansion of product indications and the acceleration of clinical promotion.
At the same time, Weiya Medical signed a strategic cooperation agreement with Guichuang Tongqiao. Guichuang Tongqiao will continue to empower the resources in the field of vascular intervention, accelerate the work of micro-sub-medical vascular intervention robot in product development, clinical cooperation, registration and commercialization, realize the coordinated development of its products and business, and meet the wider clinical needs of vascular intervention surgery.
Weiya Medical Technology Co., Ltd. was established in February, 20021,and is a high-tech enterprise dedicated to the international cutting-edge vascular interventional surgery robot. The company's main product, minimally invasive vascular interventional surgery robot, is at the international advanced and domestic leading level. In April, 20021,a new generation of surgical robots developed by Weiya Medical successfully carried out animal experiments in Fuwai Hospital, Beijing, and won unanimous praise from top cardiovascular experts in China.
In the field of vascular interventional surgery robots, Weiya Medical is a rare excellent team with more than ten years of research and development experience in China. A new generation of vascular interventional surgery robot introduced by Micromedical can perform angiography and interventional therapy of coronary artery, nerve and peripheral surgery at the same time.
Compared with other products such as overseas markets, Weiya Medical's robot products can complete surgery with robots in the whole process, and the clinical application scenarios have greatly increased.
In terms of core technology, Weiya Medical has a brand-new original delivery technology, which has achieved breakthrough upgrades in key areas such as delivery accuracy, stability and safety, and can fully meet the needs of doctors in interventional surgery. The products have been recognized by many top experts in China.
In the future, Weiya Medical will continue to deepen product upgrading, continuously improve product application ability and key technological breakthroughs, combine surgical robots with telemedicine, build an integrated platform for vascular interventional telemedicine, and contribute to the construction of vascular interventional telemedicine system.
Dr. Zhao Zhong, Chairman of Guichuang Tongqiao, said: Weiya Medical is a leader in the field of vascular interventional surgery robots in China, with profound technical accumulation and rich research and development experience of medical workers. The breakthrough technology of micro-sub-medical surgical robot products is expected to form a synergistic effect with the peripheral and nerve intervention products of Guichuang Tongqiao, realizing the technological innovation of vascular intervention and benefiting doctors and patients. We believe that this strategic investment will help the company to build a comprehensive treatment platform for vascular diseases and further enhance the market competitiveness of Guichuang Tongqiao.
Ma Jinbo, vice president of Yuan Bo Capital Investment, said: Vascular interventional surgery robot has both clinical, commercial and social values, and it is a subdivision product worthy of sustainable layout in the field of medical science and technology. We believe that micro-medicine is expected to become a leading enterprise in the field of vascular interventional surgery robots in China with its deep understanding of the clinical application of robots and the iterative ability of breakthrough technologies. Yuan Bo Capital and Guichuang Tongqiao will give full play to their respective advantages in the capital market and industry, join hands with Viagra Medical, continue to solve the unmet clinical needs with breakthrough innovative technology, and subvert the future of vascular interventional surgery with scientific and technological innovation.
The founder of Viagra Medical said: For more than 65,438+00 years, the founding team of Viagra Medical has been firmly focused on solving clinical needs, based on the research and development of underlying technologies, and committed to creating subversive products. Over the years, its intensive cultivation has achieved remarkable product results. Micro-sub-medical care will not be satisfied with the current achievements, and will continue to exert efforts in product iteration and technology research and development, and continue to explore the technological breakthrough of vascular interventional surgery robots in more complicated operations and diversified applications in telemedicine to meet the needs of doctors and patients for improving the curative effect of interventional surgery.
enclose herewith
For more project information, please visit.